SB1848Enacted

Amends TCA Title 53, Chapter 11.

Tennessee SB1848 authorizes additional healthcare providers to directly administer buprenorphine mono or buprenorphine without naloxone. The bill affects healthcare providers involved in the treatment of opioid use disorder, specifically allowing them to prescribe buprenorphine products to nursing mothers and injectable mono products without restrictions related to naloxone. Key provisions include the expansion of prescribing authority for certain healthcare providers regarding buprenorphine treatment.

What moved, what's on next week's agenda, new filings — every Monday, from the public record, free.

No account. Unsubscribe in one click.

Overview

Tennessee SB1848 authorizes additional healthcare providers to directly administer buprenorphine mono or buprenorphine without naloxone. The bill affects healthcare providers involved in the treatment of opioid use disorder, specifically allowing them to prescribe buprenorphine products to nursing mothers and injectable mono products without restrictions related to naloxone. Key provisions include the expansion of prescribing authority for certain healthcare providers regarding buprenorphine treatment.

Track Tennessee Legislation Like a Pro

Join hundreds of professionals using LegisGo to stay ahead of legislative changes.

Instant Alerts

Get notified when bills you track move through the legislature

AI Summaries

Understand complex legislation in seconds with AI-powered analysis

Full Access

All 132 legislators, committee schedules, and voting records

Sponsor

Massey, Becky

Details
Session

114th General Assembly

Introduced

January 21, 2026

Last Action

April 24, 2026

Comp. became Pub. Ch. 753

Subjects
Controlled SubstancesDrugs, Prescription

Want to track this bill? Get instant alerts and AI-powered insights.